The long game: ASX ETFs to target amidst an ageing population

These funds could be set to benefit from increased demand in global healthcare. 

Looking at trends and data can be a helpful strategy to project the success of thematic ASX ETFs.

Recent trends have seen big returns in sectors like tech and financials. 

If you were exposed to these sectors before the last couple of years, you would likely be sitting pretty today. 

One important piece of data I am aware of, is Australia's ageing population. 

A elder man and woman lean over their balcony with a cuppa, indicating share rpice movement for ASX retirement shares

Image source: Getty Images

Looking ahead

Data from the Australian Bureau of statistics shows in 2020, there were an estimated 4.2 million older Australians (aged 65 and over) – comprising 16% of the total Australian population. 

In the next 30 years, this number is projected to increase to more than 20%. 

Essentially, one in five Australians will be over the age of 65. 

Why is that the case?

Firstly, advances in healthcare, medical technology, and living standards mean Australians are living longer. 

Secondly, the baby boomer generation (born between 1946 and 1964) is progressively reaching retirement age.

As this large demographic group moves into the 65+ age bracket, it significantly increases the overall percentage of older Australians.

What does this mean for investors?

When we project this data for the long term, it makes me aware of the enormous demand for several key sectors in the decades ahead. 

One key area that is set to benefit is the healthcare sector. As we age, the demand for healthcare services increases. 

Some key ASX listed stocks that could be set to benefit include: 

  • CSL Ltd (CSL): Global leader in blood plasma, vaccines, and biotherapies.
  • Cochlear Ltd (COH): Implants for hearing loss, common in older adults.
  • ResMed Inc (ASX: RMD): Sleep apnea devices, increasingly used by ageing populations.
  • Ramsay Health Care Ltd (ASX: RHC): Operates private hospitals across Australia and globally.
  • Healius Ltd (ASX: HLS) and Sonic Healthcare Ltd (ASX: SHL) Pathology and diagnostic services.

Other key companies to monitor are those in the pharmaceuticals & biotechnology space, aged care & retirement living and wealth management. 

These areas all play an important role in caring for older Australians.

Which ASX ETFs give exposure to these sectors?

While these individual stocks may have plenty of upside, there are thematic ASX ETFs that combine hundreds of these options into one fund. 

An ageing population is not a unique problem only here in Australia.

In fact, the World Health Organisation recently revealed life expectancy at birth reached 73.3 years in 2024, an increase of 8.4 years since 1995.

The number of people aged 60 and older worldwide is projected to increase from 1.1 billion in 2023 to 1.4 billion by 2030.

Global X S&P Biotech ETF (ASX: CURE)

This fund seeks to invest in companies that potentially stand to benefit from further advances in the field of genomic science, such as companies involved in gene editing, genomic sequencing, genetic medicine/therapy, computational genomics, and biotechnology.

It is made up of roughly 124 holdings, with no individual company representing more than 3.3% of the fund.

iShares Global Healthcare ETF (ASX: IXJ)

The index is designed to measure the performance of global biotechnology, healthcare, medical equipment and pharmaceuticals companies and may include large, mid or small-capitalisation stocks.

Its largest holdings include Eli Lilly, Johnson and Johnson and ABBVIE Inc.

It also includes a small exposure to Australian companies in this sector. 

BetaShares Global Healthcare ETF – Currency Hedged (ASX: DRUG)

DRUG WTF aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. 

At the time of writing it provides access to 59 of the world's leading healthcare companies, such as Johnson & Johnson, Pfizer and Roche, in one trade.

Motley Fool contributor Aaron Bell has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL, Cochlear, Global X S&P Biotech ETF, and ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended CSL, Cochlear, and Sonic Healthcare. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Exchange-Traded Funds (ETFs)

Silhouettes of business people having a discussion with each other and speech bubbles with different national flags above them.
Exchange-Traded Funds (ETFs)

3 most popular ASX ETFs for international investing as Aussie shares underperform

In terms of growth, the ASX 200 is underperforming its global peers by a long way in CY26.

Read more »

The letters ETF with a man pointing at it.
Exchange-Traded Funds (ETFs)

My pros and cons about the Vanguard Australian Shares Index ETF (VAS)

The ASX’s largest ETF has compelling positives and eye-opening negatives.

Read more »

Man reading his emails on a laptop while relaxing on a beach.
Exchange-Traded Funds (ETFs)

How I'd build the ultimate passive income ASX ETF portfolio right now

You'll never need to touch this passive income portfolio again.

Read more »

Woman looking at her computer and pondering something.
Exchange-Traded Funds (ETFs)

Why I'd buy these Vanguard ETFs for an SMSF

I think these three funds could work well together for someone building an SMSF portfolio over the next decade or…

Read more »

Silver metallic dice showing the alphabets ETF and an up and down arrow on backgrounds of stock charts.
Exchange-Traded Funds (ETFs)

5 ASX ETFs to buy and hold for 5 years

Looking for ETFs to buy? Here are five to consider.

Read more »

ETF written in light blue on a chart.
Exchange-Traded Funds (ETFs)

Why this ASX ETF is a retiree's dream for 2027

International shares are a great call for investors, in my view.

Read more »

Senior couple enjoying each other's company while walking on the beach.
Exchange-Traded Funds (ETFs)

Is the Vanguard Australian Shares High Yield ETF (VHY) a strong buy for passive income?

Low fees, quarterly payments, and exposure to 90 Australian shares make this an ETF I'd consider for passive income.

Read more »

A man and woman watch their device screens, making investing decisions at home.
Exchange-Traded Funds (ETFs)

Should I buy the NDQ ETF after its 10% drop?

I think the recent sell-off could be an opportunity to buy some of the world's best businesses at lower prices.

Read more »